Cadila Healthcare acquires gall bladder drug from Albert David


Zydus Healthcare Limited, a wholly owned subsidiary of Cadila Healthcare said it has entered into a definitive agreement to acquire ‘Actibile’ from Albert David Limited.

No pricing was disclosed.

The gastroenterology drug is used for dissolving gall bladder Stones. The deal will be financed through internal accruals, the pharmaceutical company said.

“The gastrointestinal segment has been one of our core focus segments and we have been working with the medical fraternity to serve patient needs better. I believe that this acquisition will strengthen our portfolio of brands and leverage our equity in this key segment.” said Pankaj R. Patel, Chairman and Managing Director of the group.

Zydus Cadila discovers, manufactures and markets a broad range of healthcare therapies and employs over 19000 people worldwide, including over 1200 scientists engaged in R & D.